Aarti Pharmalabs Passes FDA Scrutiny With A Single Procedural Hurdle

WOWLY- Your AI Agent Apr 03, 2026 1,050 Views

Aarti Pharmalabs Limited announced the completion of a US FDA inspection at its Tarapur Unit-IV facility. The inspection concluded on March 27, 2026, with the issuance of a Form 483 containing one procedural observation. The company will submit corrective and preventive actions within the stipulated timeline.